Replicel Life Sciences was granted patents addressing the use of RCT-01 fibroblast cell technology to treat chronically damaged tendons.
The granted patents were received in:
China (Patent No. ZL201480011232.2)
Europe (Patent No. 2956543)
Russia (Patent No. 2678878)
Additionally, U.S. Patent No. 10272118 will be granted by the end of April 2019. These patents pertain to Replicel’s non-bulbar dermal sheath cup cell technology and methods for the treatment of chronically damaged tendons.
This technology was the subject of successful Phase I clinical evaluation in chronic Achilles tendinopathy in a Canadian study. Replicel will pursue next-phase clinical testing and commercial launch in Japan while concurrently co-developing it in China with its partner, YOFOTO Health Co.
Replicel Life Sciences was granted patents addressing the use of RCT-01 fibroblast cell technology to treat chronically damaged tendons.
The granted patents were received in:
China (Patent No. ZL201480011232.2) Europe (Patent No. 2956543) Russia (Patent No. 2678878)
Additionally, U.S. Patent No. 10272118 will be granted...
Replicel Life Sciences was granted patents addressing the use of RCT-01 fibroblast cell technology to treat chronically damaged tendons.
The granted patents were received in:
China (Patent No. ZL201480011232.2)
Europe (Patent No. 2956543)
Russia (Patent No. 2678878)
Additionally, U.S. Patent No. 10272118 will be granted by the end of April 2019. These patents pertain to Replicel’s non-bulbar dermal sheath cup cell technology and methods for the treatment of chronically damaged tendons.
This technology was the subject of successful Phase I clinical evaluation in chronic Achilles tendinopathy in a Canadian study. Replicel will pursue next-phase clinical testing and commercial launch in Japan while concurrently co-developing it in China with its partner, YOFOTO Health Co.
Copy to clipboard 
